EUCTR2011-005249-12-PL进行中（未招募）不适用
A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis with Relapsing Forms of Multiple Sclerosis Followed byan Open-Label Extension - TERIKIDS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients with relapsing multiple sclerosis are eligible. Patients should meet the criteria of MS based on McDonald criteria 2010 and International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, version of 2012 (5) and have:
- •- at least one relapse (or attack) in the 12 months preceding randomization or
- •- at least two relapses (or attack) in the 24 months preceding randomization
- •-=17 years of age and =10 years of age at randomization
- •-Signed informed consent/assent obtained from patient and patient's legal representative (parents or guardians) according to local regulations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 165
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •EDSS score > 5.5 at screening or randomization visits
- •Relapse within 30 days prior to randomization
- •Treated with
- •- glatiramer acetate, interferons, or dimethyl fumarate within 1 month prior to randomization
- •- fingolimod, or intravenous immunoglobulins within 3 months prior to randomization
- •- natalizumab, other immunosuppressant or immunomodulatory agents such as cyclophosphamide, azathioprine, cyclosporine, methotrexate, mycophenolate, within 6 months prior to randomization
- •- cladribine or mitoxantrone within 2 years prior to randomization
- •Treated with alemtuzumab at any time
- •History of HIV infection
- •Contraindication for MRI
- •Pregnant or breast-feeding females or those who plan to become pregnant during the study
- •Female patients of child-bearing potential not using highly effective contraceptive method (contraception in both female and male is required).
研究者
相似试验
进行中（未招募）
1 期
A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosisMultiple SclerosisEUCTR2011-005249-12-ESGenzyme Corporation165
进行中（未招募）
1 期
A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosisMedDRA version: 18.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2011-005249-12-FRGenzyme Corporation166
进行中（未招募）
不适用
A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment of osteoporosis in men - NATreatment of osteoporosis in menMedDRA version: 8.1Level: LLTClassification code 10031282Term: OsteoporosisEUCTR2004-004131-57-FIovartis Pharma Services AG1,072
进行中（未招募）
不适用
A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment of osteoporosis in men - NATreatment of osteoporosis in menEUCTR2004-004131-57-DEovartis Pharma Services AG1,072
进行中（未招募）
不适用
A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment of osteoporosis in men - NATreatment of osteoporosis in menEUCTR2004-004131-57-BEovartis Pharma Services AG1,072